Literature DB >> 16220627

Medical research, risk, and bystanders.

Jonathan Kimmelman1.   

Abstract

Keywords:  Analytical Approach; Biomedical and Behavioral Research

Mesh：

Substances：

Year:  2005        PMID： 16220627

Source DB:  PubMed          Journal:  IRB        ISSN： 0193-7758


× No keyword cloud information.
  9 in total

Review 1.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

2.  Protecting third parties in human subjects research.

Authors:  David B Resnik; Richard R Sharp
Journal:  IRB       Date:  2006 Jul-Aug

3.  Human Immunodeficiency Virus Transmission Risk in Analytical Treatment Interruption Studies: Relational Factors and Moral Responsibility.

Authors:  Liza Dawson
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

Review 4.  Regulating impact on bystanders in clinical trials: An unsettled frontier.

Authors:  Nir Eyal; Jonathan Kimmelman; Lisa G Holtzman; Marc Lipsitch
Journal:  Clin Trials       Date:  2019-08-01       Impact factor: 2.486

5.  Bystanders, risks, and consent.

Authors:  Helen Frowe
Journal:  Bioethics       Date:  2019-10-25       Impact factor: 1.898

6.  Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies.

Authors:  Susan M Wolf; Cortney Jones
Journal:  J Nanopart Res       Date:  2011-04       Impact factor: 2.253

Review 7.  Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy.

Authors:  Euzebiusz Jamrozik; Michael J Selgelid
Journal:  J Med Ethics       Date:  2020-05-07       Impact factor: 2.903

8.  How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach.

Authors:  Nir Eyal
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

9.  Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium.

Authors:  Nir Eyal; Steven G Deeks
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.